The SOLO‐1 trial showed that first‐line maintenance therapy with Olaparib, an oral poly‐adenosine diphosphate‐ribose polymerase inhibitor (PARPi), significantly improved survival in patients with newly diagnosed advanced ovarian carcinoma that had germline or somatic BRCA1/2 gene mutations [7]. Here, BRCA1 is linked to ovarian carcinoma.